Tuesday, March 19, 2024
ISSN 2765-8767
  • Home
  • About Us
  • Contact us
  • Support Us
  • Home
  • About Us
  • Contact us
  • Support Us

A cheap antidepressant is showing promise treating COVID-19 in high-risk adults

A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.

Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.

They’ve shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.

Source: NPR

https://www.npr.org/2021/10/28/1050202177/antidepressant-fluvoxamine-covid-19-treatment

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Why are health insurance premiums going up?

How do you envision death?

How do you envision death?

As society entered the era of modern medicine, people developed a new understanding of death. Artist John Downman portrays two star-crossed lovers meeting for the last time: Edwin and Emma. For these two lovers, death is a welcomed reprieve from a life of sadness and separation.

Read more

Newsletter

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do